Andrew Jackson/LinkedIn
Aug 15, 2026, 16:58
Andrew Jackson: Oral Anticoagulants for the Prophylaxis of Catheter-Related Thrombosis
Andrew Jackson, Owner of IVTEAM LTD, shared a post on LinkedIn:
”Oral anticoagulants for the prophylaxis of catheter-related thrombosis
‘Prophylactic use of apixaban or rivaroxaban significantly reduces catheter-associated thrombosis and prolongs catheter survival compared with placebo, without an increased risk of bleeding’
Soliman et al (2026).”
Stay updated with Hemostasis Today.
-
Aug 15, 2026, 17:50Muhammad Shaheer Bin Faheem: 25 Years of Thromboembolism and Hypertension Mortality
-
Aug 15, 2026, 17:21Bilal Salman։ NETosis as a Therapeutic Target in Inflammation and Thrombosis
-
Aug 15, 2026, 16:52Understanding Blood Clots During Pregnancy and After Birth – Thrombosis UK
-
Aug 15, 2026, 16:39Liri Seraj: How Summer Dehydration Affects Blood and Thrombosis Risk
-
Aug 15, 2026, 16:29Denise Rezende: What Should Clinicians Do When Thrombosis Occurs Despite DOAC Therapy?
-
Aug 15, 2026, 16:20Anoop Singh: When India Became the Key to a Faster Hemophilia A Trial
-
Aug 15, 2026, 16:10Swarup K Chakrabarti: Why the Blood–Brain Barrier Matters for Healthy Aging
-
Aug 15, 2026, 16:00Satya Prakash Yadav: Overcoming Overtreatment in Pediatric Immune Thrombocytopenia
-
Aug 15, 2026, 15:54Clare Craig: Examining Post-Pandemic Healthcare Disruption and Thrombocytopenia Risks